Posted on January 4, 2019 by Sitemaster
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
Posted on October 26, 2015 by Sitemaster
Historically there has been a perception that risk for diagnosis with and death from prostate cancer among men of East Asian ethnicity was lower than that among men of European/Caucasian ethnicity. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: asian, Eastern, ethnicity, incidence, mortality, prevalence, risk | Leave a comment »
Posted on October 22, 2015 by Sitemaster
A newly published paper in the journal PLoSOne has addressed the future prevalence of various different clinical states of prostate cancer here in the USA, along with the mortality of the men diagnosed with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: estimate, incidence, model, mortality, prevalence | Leave a comment »
Posted on May 29, 2015 by Sitemaster
The ability to recover good erectile function after treatment for localized prostate cancer is — rather obviously — dependent on the quality of patients’ erectile function prior to any treatment. However, good data on this latter factor is not as well documented as one might like. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: dysfunction, erectile, function, prevalence | 1 Comment »
Posted on October 7, 2014 by Sitemaster
A new study just published yesterday in the Journal of Clinical Oncology provides some interesting insights into the risk for various types of mental and emotional distress associated with diagnosis and treatment of cancer among > 2,100 patients with cancer interviewed according to a standardized protocol in Germany. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: anxiety, distress, mental health, prevalence | 1 Comment »
Posted on July 6, 2012 by Sitemaster
It has long been a tenet of prostate cancer therapy (whether correct or not) that the appearance of evident metastasis (M1 disease) in men with supposedly progressive, micrometastatic (M0) disease is a key event in the management of patients because of the association between evident metastasis and the potential for onset of symptomatic bone disease. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: metastasis, prevalence, significance | 8 Comments »
Posted on June 23, 2012 by Sitemaster
A new article in CA: A Cancer Journal for Clinicians provides updated issues on the numbers of people surviving after a diagnosis of cancer in America, and includes data specific to prostate cancer survival. The full text of this article is available on line. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: care plan, prevalence, survivorship | 18 Comments »
Posted on May 24, 2011 by Sitemaster
One of the posters to be presented at the upcoming annual meeting of the American Society of Clinical Oncology offers an interesting model permitting replicative estimation of the numbers of patients living with different clinical stages of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: clinical status, epidemiology, prevalence, stage | 4 Comments »
Posted on March 15, 2011 by Sitemaster
A report from the Centers for Disease Control, issued last week, suggests that as of January 1, 2007 there were nearly 2.3 million men living in the U.S. after a diagnosis of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: prevalence, USA | 2 Comments »
Posted on March 10, 2011 by Sitemaster
Vitamin D insufficiency is currently defined as a serum level 25-hydroxy vitamin D that is less than 75 nmol/l. (And there are many who think that a higher minimum level might be appropriate.) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: insufficiency, prevalence, vitamin D | 8 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 